Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108914 · ClinicalTrials.gov registry record · Phase 3
Perennial Allergic Rhinitis Study In Pediatric Subjects
A Phase 3 study of Rhinitis, Allergic, Perennial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 558
- Enrollment target
- 20
- Study locations
NCT00108914 is a Phase 3 study of Rhinitis, Allergic, Perennial that has completed, run by GlaxoSmithKline. The registered enrollment target is 558 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT00108914, a Phase 3 study of Rhinitis, Allergic, Perennial, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 558 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if the investigational drug is effective and safe in children with perennial allergic rhinitis.
Conditions Studied
Interventions
- DRUG GW685698X
Study Locations (20)
California
- GSK Investigational Site - Costa Mesa
- GSK Investigational Site - Cudahy
- GSK Investigational Site - Long Beach
- GSK Investigational Site - Long Beach
- GSK Investigational Site - Orange
- GSK Investigational Site - Riverside
- GSK Investigational Site - Sacramento
- GSK Investigational Site - San Diego
- GSK Investigational Site - San Diego
- GSK Investigational Site - Walnut Creek
Colorado
- GSK Investigational Site - Denver
- GSK Investigational Site - Denver
- GSK Investigational Site - Englewood
Georgia
- GSK Investigational Site - Gainesville
- GSK Investigational Site - Lawrenceville
- GSK Investigational Site - Stockbridge
Louisiana
- GSK Investigational Site - Metairie
- GSK Investigational Site - Shreveport
Florida
- GSK Investigational Site - Coral Gables
Maryland
- GSK Investigational Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 558 participants |
| Start Date | 2005-02 |
| Est. Completion | 2005-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00108914
The ClinicalTrials.gov registry entry for NCT00108914 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 558 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rhinitis, Allergic, Perennial appearing as the primary indexed condition, and to 1 intervention - of which GW685698X is the first listed.
NCT00108914 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Colorado, Georgia.
Frequently Asked Questions
What is clinical trial NCT00108914 about?
NCT00108914 is a clinical study titled "Perennial Allergic Rhinitis Study In Pediatric Subjects". The purpose of this study is to determine if the investigational drug is effective and safe in children with perennial allergic rhinitis.
What is the current status of trial NCT00108914?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 558 participants. The study started on 2005-02. Estimated completion is 2005-11.
What conditions does trial NCT00108914 study?
This clinical trial studies the following conditions: Rhinitis, Allergic, Perennial.
What interventions are being tested in trial NCT00108914?
The interventions under investigation include: GW685698X (DRUG).
Who is sponsoring clinical trial NCT00108914?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00108914 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rhinitis, Allergic, Perennial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.